THERAPY DOSSIER · th-506b0415c50c

(R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153)

Drug · MS-153 is a glutamate transporter (GLT-1/EAAT2) activator (research tool); no confident ChEMBL name match returned

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: MS-153 is a glutamate transporter (GLT-1/EAAT2) activator (research tool); no confident ChEMBL name match returned
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26200170 ↗2015Reported benefit

Neuroprotective Effects of the Glutamate Transporter Activator (R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153) following Traumatic Brain Injury in the Adult Rat.

RatTBIUnspecifiedSprague-DawleyMaleBeginning immediately after injury and continuing for 24 h

Model: Experimental traumatic brain injury in the adult rat, with sham-injured controls (specific impact method not stated in the available text)

EAAT2 activity (Vmax) in cortex and hippocampus fell significantly from 5 min up to 2 h after brain trauma, with no change in glutamate affinity or in GLT-1 and GLAST expression. MS-153 given immediately after injury and continued for 24 h significantly reduced neurodegeneration, loss of MAP2 and N…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…